Abstract
This Frost & Sullivan research service titled European Asthma Therapeutics
Markets provides key challenges, forecasts and recommendations for the asthma
therapeutics market. In this research, Frost & Sullivan' s expert analysts
thoroughly examine the following markets: short acting beta 2 agonists,
inhaled corticosteroids, combination therapies and leukotriene antagonists.
This analysis is available through our Pharmaceuticals and Biotechnology
Growth Partnership Service programme. With this programme, clients receive
industry-leading market research such as this, along with technical and
econometric data and many interactive features including Analyst Inquiry Time
and Client Councils.
|